Blog

Novel approach may prolong remission after T-cell immunotherapy for leukemia, lymphoma – Healio

Novel approach may prolong remission after T-cell immunotherapy for leukemia, lymphoma
Healio
Researchers at Seattle Children's Hospital have launched a first-in-human trial to investigate whether infusions of T-cell antigen–presenting cells prolong the persistence of chimeric antigen receptor T-cell immunotherapy among children with relapsed

2017-06-26 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.